Somsri Wiwanitkit1, Viroj Wiwanitkit2. Show Affiliations » 1. Wiwanitkit House, Bangkhae, Bangkok, Thailand. 2. Department of Biological Science, Joseph Ayo Babalola University, Ilesa, Osun, Nigeria.
Abstract
Entities: Disease
Mesh： See more » Cost-Benefit AnalysisFemaleHuman Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/adverse effectsHuman Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/economicsHuman Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/therapeutic useHumansPapillomavirus Vaccines/adverse effectsPapillomavirus Vaccines/economicsPapillomavirus Vaccines/therapeutic useThailandUterine Cervical Neoplasms/economicsUterine Cervical Neoplasms/immunologyUterine Cervical Neoplasms/prevention & control
Substances： See more » Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18Papillomavirus Vaccineshuman papillomavirus vaccine, L1 type 16, 18
Year: 2019 PMID： 31898687 DOI： 10.4103/jcrt.JCRT_415_18
Source DB: PubMed Journal: J Cancer Res Ther ISSN： 1998-4138 Impact factor: 1.805